Kane Biotech Inc. (CVE:KNE – Get Free Report) shares traded down 14.3% on Tuesday . The company traded as low as C$0.03 and last traded at C$0.03. 101,404 shares were traded during trading, a decline of 46% from the average session volume of 187,188 shares. The stock had previously closed at C$0.04.
Kane Biotech Price Performance
The company has a debt-to-equity ratio of -308.66, a current ratio of 0.68 and a quick ratio of 0.39. The stock’s 50 day simple moving average is C$0.03 and its two-hundred day simple moving average is C$0.04. The stock has a market cap of C$6.36 million, a price-to-earnings ratio of -1.75 and a beta of 1.03.
Kane Biotech Company Profile
Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand.
Read More
- Five stocks we like better than Kane Biotech
- Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending
- As Small-Cap Outperformance Continues, These 2 ETFs Provide Exposure
- Silicon Shake-Up: The AI Trade Is Moving Beyond NVIDIA
- The Silver Lining of Last Week’s Hims & Hers Earnings Miss
Receive News & Ratings for Kane Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kane Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
